{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:17:15Z","timestamp":1789215435695,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007238","name":"Office of Women's Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dmd.2026.100271","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:05:21Z","timestamp":1774598721000},"page":"100271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanistic prediction of apixaban and rivaroxaban secretion into human milk and infant systemic exposure through an integrated physiologically based pharmacokinetic framework"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9630-4258","authenticated-orcid":false,"given":"Bofang","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allesandra","family":"Stratigakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Asikur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-3144","authenticated-orcid":false,"given":"Xinrui (Sarea)","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-8230","authenticated-orcid":false,"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10017","key":"10.1016\/j.dmd.2026.100271_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(15)01024-7","article-title":"Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect","volume":"387","author":"Victora","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pcl.2012.10.002","article-title":"Human milk composition: nutrients and bioactive factors","volume":"60","author":"Ballard","year":"2013","journal-title":"Pediatr Clin North Am"},{"issue":"2 Suppl","key":"10.1016\/j.dmd.2026.100271_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jpeds.2009.11.021","article-title":"Breast milk as the gold standard for protective nutrients","volume":"156","author":"Walker","year":"2010","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.dmd.2026.100271_bib4","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1542\/peds.2006-2256","article-title":"Breastfeeding and hospitalization for diarrheal and respiratory infection in the United Kingdom Millennium Cohort Study","volume":"119","author":"Quigley","year":"2007","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.dmd.2026.100271_bib5","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S2214-109X(15)70002-1","article-title":"Association between breastfeeding and intelligence, educational attainment, and income at 30 years of age: a prospective birth cohort study from Brazil","volume":"3","author":"Victora","year":"2015","journal-title":"Lancet Glob Health"},{"issue":"467","key":"10.1016\/j.dmd.2026.100271_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/apa.13102","article-title":"Breastfeeding and maternal health outcomes: a systematic review and meta-analysis","volume":"104","author":"Chowdhury","year":"2015","journal-title":"Acta Paediatr"},{"issue":"9328","key":"10.1016\/j.dmd.2026.100271_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(02)09454-0","article-title":"Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease","volume":"360","author":"Beral","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.dmd.2026.100271_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.13401","article-title":"Association of maternal lactation with diabetes and hypertension: a systematic review and meta-analysis","volume":"2","author":"Rameez","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.dmd.2026.100271_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022746","article-title":"Breastfeeding is associated with a reduced maternal cardiovascular risk: systematic review and meta-analysis involving data from 8 studies and 1 192 700 parous women","volume":"11","author":"Tschiderer","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.dmd.2026.100271_bib10","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.1542\/peds.2013-1985","article-title":"The transfer of drugs and therapeutics into human breast milk: an update on selected topics","volume":"132","author":"Sachs","year":"2013","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100271_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJM200007133430208","article-title":"Drug therapy for breast-feeding women","volume":"343","author":"Ito","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.dmd.2026.100271_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11095-017-2287-z","article-title":"Drugs in lactation","volume":"35","author":"Anderson","year":"2018","journal-title":"Pharm Res"},{"issue":"5-6","key":"10.1016\/j.dmd.2026.100271_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/bdd.70018","article-title":"Development of a physiologically based pharmacokinetic (PBPK) simulation model for nicotine","volume":"46","author":"Kim","year":"2025","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100271_bib14","first-page":"594","article-title":"Drug use during breast-feeding","volume":"10","author":"Anderson","year":"1991","journal-title":"Clin Pharm"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/pharmaceutics17060719","article-title":"The impact of substance use disorder and drug transfer into breast milk: implications for maternal and infant health","volume":"17","author":"Yang","year":"2025","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.dmd.2026.100271_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2125.1992.tb04077.x","article-title":"Prospective evaluation of a model for the prediction of milk:plasma drug concentrations from physicochemical characteristics","volume":"33","author":"Begg","year":"1992","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","article-title":"Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling","volume":"51","author":"Abduljalil","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/bdd.2335","article-title":"Physiologically based pharmacokinetic model to predict drug concentrations of breast cancer resistance protein substrates in milk","volume":"43","author":"Zhang","year":"2022","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100271_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2014.45","article-title":"Physiologically based pharmacokinetic modeling and simulation in pediatric drug development","volume":"3","author":"Maharaj","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40262-017-0594-5","article-title":"A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways","volume":"57","author":"Dallmann","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2026.100271_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.733823","article-title":"Maternal-fetal pharmacology of drugs: a review of current status of the application of physiologically based pharmacokinetic models","volume":"9","author":"Chaphekar","year":"2021","journal-title":"Front Pediatr"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103767","article-title":"Microfluidic blood-milk barrier and physiologically based pharmacokinetic model to predict lofexidine secretion into breast milk","volume":"114","author":"Dash","year":"2025","journal-title":"J Pharm Sci"},{"issue":"15","key":"10.1016\/j.dmd.2026.100271_bib23","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.dmd.2026.100271_bib24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.dmd.2026.100271_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100271_bib28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100271_bib29","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/bcp.70032","article-title":"Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban","volume":"91","author":"Gaspar","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2026.100271_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2024.124425","article-title":"Effect of furmonertinib on the pharmacokinetics of rivaroxaban or apixaban in vivo","volume":"1251","author":"Wang","year":"2025","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bcpt.13794","article-title":"Are active efflux transporters contributing to infant drug exposure via breastmilk? A longitudinal study","volume":"131","author":"Ahmadzai","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100271_bib32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/MCB.01621-06","article-title":"Multidrug transporter ABCG2\/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk","volume":"27","author":"van Herwaarden","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0031-3955(05)70462-4","article-title":"Breast-feeding and maternal drug use","volume":"44","author":"Bailey","year":"1997","journal-title":"Pediatr Clin North Am"},{"issue":"5","key":"10.1016\/j.dmd.2026.100271_bib34","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1124\/mol.104.010439","article-title":"The breast cancer resistance protein (BCRP\/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin","volume":"67","author":"Merino","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100271_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00062-22","article-title":"Secretion into milk of the main metabolites of the anthelmintic albendazole is mediated by the ABCG2\/BCRP transporter","volume":"66","author":"Blanco-Paniagua","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmd.2026.100271_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.thromres.2024.04.003","article-title":"Potential treatment option of rivaroxaban for breastfeeding women: a case series","volume":"237","author":"Yamashita","year":"2024","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100271_bib37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/psp4.13090","article-title":"Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: prediction of primaquine exposure as a case example","volume":"13","author":"Pan","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cpt.2912","article-title":"Physiologically based pharmacokinetic modeling to determine the impact of CYP2B6 genotype on efavirenz exposure in children, mothers and breastfeeding infants","volume":"114","author":"Pan","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100271_bib39","article-title":"An in vitro human mammary epithelial cell permeability assay to assess drug secretion into breast milk","volume":"4","author":"Zhang","year":"2022","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.dmd.2026.100271_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.023","article-title":"Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells","volume":"394","author":"Burnett","year":"2017","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib41","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.124.001824","volume":"53","author":"Al-Majdoub","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100271_bib42","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpt.1693","article-title":"Physiologically-based pharmacokinetic models for evaluating membrane transporter mediated drug-drug interactions: current capabilities, case studies, future opportunities, and recommendations","volume":"107","author":"Taskar","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib43","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/AOG.0000000000004388","article-title":"Transfer of apixaban into human milk","volume":"137","author":"Datta","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"15","key":"10.1016\/j.dmd.2026.100271_bib44","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2020006231","article-title":"Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?","volume":"136","author":"Zhao","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.dmd.2026.100271_bib45","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1089\/bfm.2019.0230","article-title":"Rivaroxaban concentration in breast milk during breastfeeding: a case study","volume":"14","author":"Saito","year":"2019","journal-title":"Breastfeed Med"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib46","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2016.01.021","article-title":"The direct factor Xa inhibitor rivaroxaban passes into human breast milk","volume":"150","author":"Wiesen","year":"2016","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.dmd.2026.100271_bib47","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.dmd.2026.100271_bib48","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/psp4.13036","article-title":"Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: a first step for larger use of a priori modeling approach at bed side","volume":"12","author":"Terrier","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2026.100271_bib49","series-title":"StatPearls [Internet]","author":"Agrawal","year":"2025"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib50","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.dmd.2026.100271_bib51","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1111\/bcp.14743","article-title":"Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations","volume":"87","author":"Xu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100271_bib52","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100271_bib53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.beem.2017.10.008","article-title":"Physiology of milk secretion","volume":"31","author":"Truchet","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ca.22165","article-title":"Anatomy of the human mammary gland: current status of knowledge","volume":"26","author":"Hassiotou","year":"2013","journal-title":"Clin Anat"},{"issue":"10","key":"10.1016\/j.dmd.2026.100271_bib55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100271_bib56","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0163-7258(93)90072-L","article-title":"Modelling of the passage of drugs into milk","volume":"59","author":"Begg","year":"1993","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100271_bib57","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0169-409X(03)00032-2","article-title":"Models and methods for predicting drug transfer into human milk","volume":"55","author":"Fleishaker","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1016\/j.dmd.2026.100271_bib58","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1345\/aph.1C379","article-title":"Prediction of milk\/plasma concentration ratio of drugs","volume":"37","author":"Larsen","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.dmd.2026.100271_bib59","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1124\/dmd.111.040972","article-title":"Analysis and prediction of drug transfer into human milk taking into consideration secretion and reuptake clearances across the mammary epithelia","volume":"39","author":"Koshimichi","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100271_bib60","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1021\/acs.molpharmaceut.2c00193","article-title":"Developing an in vitro to in vivo extrapolation (IVIVE) model to predict human milk-to-plasma drug concentration ratios","volume":"19","author":"Yang","year":"2022","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.dmd.2026.100271_bib61","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cpt.3354","article-title":"Age-dependent abundance of CYP450 enzymes involved in metronidazole metabolism: application to pediatric PBPK modeling","volume":"116","author":"Parvez","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100271_bib62","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/psp4.12935","article-title":"Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder","volume":"12","author":"Merali","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40262-013-0090-5","article-title":"Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban","volume":"53","author":"Willmann","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.dmd.2026.100271_bib64","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/psp4.13232","article-title":"A tutorial on physiologically based pharmacokinetic approaches in lactation research","volume":"13","author":"Pansari","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2026.100271_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251319961","article-title":"Evaluation of rivaroxaban exposure via anti-Xa levels during VTE prophylaxis in hospitalized patients","volume":"31","author":"Blotske","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1016\/j.dmd.2026.100271_bib66","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/genes11040438","article-title":"Interindividual variability of apixaban plasma concentrations: influence of clinical and genetic factors in a real-life cohort of atrial fibrillation patients","volume":"11","author":"Ro\u015fian","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.dmd.2026.100271_bib67","series-title":"Drugs and Lactation Database (LactMed\u00ae) [Internet]","year":"2006"},{"issue":"3","key":"10.1016\/j.dmd.2026.100271_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10928-025-09972-9","article-title":"Machine learning approaches for assessing medication transfer to human breast milk","volume":"52","author":"Zhao","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.dmd.2026.100271_bib69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2015.03.011","article-title":"In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review","volume":"86","author":"Lambrinidis","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.dmd.2026.100271_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4757-4242-8_4","article-title":"Human milk proteins: key components for the biological activity of human milk","volume":"554","author":"L\u00f6nnerdal","year":"2004","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100271_bib71","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.earlhumdev.2015.08.013","article-title":"Human breast milk: a review on its composition and bioactivity","volume":"91","author":"Andreas","year":"2015","journal-title":"Early Hum Dev"},{"issue":"1","key":"10.1016\/j.dmd.2026.100271_bib72","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cpt.377","article-title":"Modeling drug passage into human milk","volume":"100","author":"Anderson","year":"2016","journal-title":"Clin Pharmacol Therap"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib73","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.dmd.2026.100271_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70417","article-title":"Optimization of bottom-up PBPK model development in SIMCYP via retrospective analysis of clinical human PK data","volume":"18","author":"Schulz Pauly","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"10","key":"10.1016\/j.dmd.2026.100271_bib75","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1124\/dmd.121.000538","article-title":"Successful prediction of human fetal exposure to P-glycoprotein substrate drugs using the proteomics-informed relative expression factor approach and PBPK modeling and simulation","volume":"49","author":"Anoshchenko","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100271_bib76","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/psp4.12619","article-title":"PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction","volume":"10","author":"Bolleddula","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100271_bib77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11095-013-1163-8","article-title":"Compartmental models for apical efflux by P-glycoprotein: part 2--a theoretical study on transporter kinetic parameters","volume":"31","author":"Korzekwa","year":"2014","journal-title":"Pharm Res"},{"issue":"20","key":"10.1016\/j.dmd.2026.100271_bib78","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1111\/febs.16124","article-title":"A guide to the Michaelis-Menten equation: steady state and beyond","volume":"289","author":"Srinivasan","year":"2022","journal-title":"FEBS J"},{"issue":"2","key":"10.1016\/j.dmd.2026.100271_bib79","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jtha.2025.09.040","article-title":"Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed-a physiologically based pharmacokinetic analysis","volume":"24","author":"Butler","year":"2026","journal-title":"J Thromb Haemost"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:15:31Z","timestamp":1779790531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0090955626000401"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100271","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic prediction of apixaban and rivaroxaban secretion into human milk and infant systemic exposure through an integrated physiologically based pharmacokinetic framework","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100271"}}